Denali Therapeutics (DNLI) Other Gross PP&E Adjustments (2017 - 2025)
Denali Therapeutics (DNLI) has disclosed Other Gross PP&E Adjustments for 9 consecutive years, with -$20.0 million as the latest value for Q3 2025.
- On a quarterly basis, Other Gross PP&E Adjustments rose 48.21% to -$20.0 million in Q3 2025 year-over-year; TTM through Sep 2025 was -$20.0 million, a 48.21% increase, with the full-year FY2024 number at $2.0 million, down 94.84% from a year prior.
- Other Gross PP&E Adjustments was -$20.0 million for Q3 2025 at Denali Therapeutics, up from -$47.4 million in the prior quarter.
- In the past five years, Other Gross PP&E Adjustments ranged from a high of $38.4 million in Q4 2023 to a low of -$50.2 million in Q1 2025.
- A 5-year average of -$22.1 million and a median of -$28.0 million in 2023 define the central range for Other Gross PP&E Adjustments.
- Peak YoY movement for Other Gross PP&E Adjustments: soared 500.22% in 2023, then plummeted 98.34% in 2025.
- Denali Therapeutics' Other Gross PP&E Adjustments stood at $7.3 million in 2021, then fell by 12.21% to $6.4 million in 2022, then skyrocketed by 500.22% to $38.4 million in 2023, then crashed by 94.84% to $2.0 million in 2024, then plummeted by 1112.38% to -$20.0 million in 2025.
- Per Business Quant, the three most recent readings for DNLI's Other Gross PP&E Adjustments are -$20.0 million (Q3 2025), -$47.4 million (Q2 2025), and -$50.2 million (Q1 2025).